Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.37 |
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19644967 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL646134 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL17117149 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL17109576 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL2722884 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL13519758 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL31228150 | 0.90 | ADORA2A (0.36) | ADORA2APOLRMTPRMT5WDR77DOT1L | |
| SCHEMBL15682916 | 0.89 | ADORA2A (0.39) | ADORA2APOLRMTADORA3DOT1LPI4KA | |
| SCHEMBL17615387 | 0.87 | ADORA2A (0.38) | ADORA2APOLRMTADORA3DOT1LPI4KA | |
| SCHEMBL18697877 | 0.87 | ADORA2A (0.38) | ADORA2APOLRMTADORA3DOT1LPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | ADORA2A 3132/4885ADA 391/4885POLRMT 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.